Rationale and design of the oral HEMe iron polypeptide Against Treatment with Oral Controlled Release Iron Tablets trial for the correction of anaemia in peritoneal dialysis patients (HEMATOCRIT trial) by Barraclough, Katherine A et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Nephrology
Open Access Study protocol
Rationale and design of the oral HEMe iron polypeptide Against 
Treatment with Oral Controlled Release Iron Tablets trial for the 
correction of anaemia in peritoneal dialysis patients 
(HEMATOCRIT trial)
Katherine A Barraclough1, Euan Noble1, Diana Leary1, Fiona Brown2, 
Carmel M Hawley1,3, Scott B Campbell1, Nicole M Isbel1, David W Mudge1, 
Carolyn L van Eps1, Joanna M Sturtevant1 and David W Johnson*1,3
Address: 1Department of Nephrology, University of Queensland at Princess Alexandra Hospital, Brisbane, Australia, 2Department of Nephrology, 
Monash Medical Centre, Melbourne, Australia and 3Australasian Kidney Trials Network, School of Population Health, University of Queensland, 
Brisbane Australia
Email: Katherine A Barraclough - katherine_barraclough@health.qld.gov.au; Euan Noble - euan.noble@addenbrookes.nhs.uk; 
Diana Leary - diana_leary@health.qld.gov.au; Fiona Brown - Fiona.Brown@med.monash.edu.au; 
Carmel M Hawley - carmel_hawley@health.qld.gov.au; Scott B Campbell - scottB_campbell@health.qld.gov.au; 
Nicole M Isbel - nikki_isbel@health.qld.gov.au; David W Mudge - david_mudge@health.qld.gov.au; Carolyn L van 
Eps - Carolyn_vaneps@health.qld.gov.au; Joanna M Sturtevant - jo_sturtevant@health.qld.gov.au; 
David W Johnson* - david_johnson@health.qld.gov.au
* Corresponding author    
Abstract
Background: The main hypothesis of this study is that oral heme iron polypeptide (HIP; Proferrin® ES)
administration will more effectively augment iron stores in erythropoietic stimulatory agent (ESA)-treated
peritoneal dialysis (PD) patients than conventional oral iron supplementation (Ferrogradumet®).
Methods:  Inclusion criteria are peritoneal dialysis patients treated with darbepoietin alpha (DPO;
Aranesp®, Amgen) for ≥ 1 month. Patients will be randomized 1:1 to receive either slow-release ferrous
sulphate (1 tablet twice daily; control) or HIP (1 tablet twice daily) for a period of 6 months. The study
will follow an open-label design but outcome assessors will be blinded to study treatment. During the 6-
month study period, haemoglobin levels will be measured monthly and iron studies (including transferring
saturation [TSAT] measurements) will be performed bi-monthly. The primary outcome measure will be
the difference in TSAT levels between the 2 groups at the end of the 6 month study period, adjusted for
baseline values using analysis of covariance (ANCOVA). Secondary outcome measures will include serum
ferritin concentration, haemoglobin level, DPO dosage, Key's index (DPO dosage divided by haemoglobin
concentration), and occurrence of adverse events (especially gastrointestinal adverse events).
Discussion: This investigator-initiated multicentre study has been designed to provide evidence to help
nephrologists and their peritoneal dialysis patients determine whether HIP administration more effectively
augments iron stores in ESP-treated PD patients than conventional oral iron supplementation.
Trial Registration: Australia New Zealand Clinical Trials Registry number ACTRN12609000432213.
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Background
Anemia develops early in the course of chronic kidney dis-
ease (CKD) and is nearly universal in patients with CKD
stage 5 [1]. The severity of anemia is related to both the
degree of loss of glomerular filtration rate (GFR) and the
cause of kidney disease [2]. The development of erythro-
poietic stimulatory agents (ESA), such as recombinant
human erythropoietin (EPO) and darbepoietin alpha
(DPO), has resulted in substantial health benefits for
patients with end-stage renal failure, including improved
quality of life, reduced blood transfusion requirements,
decreased left ventricular mass, diminished sleep distur-
bance and enhanced exercise capacity [3,4]. Unfortu-
nately, a considerable proportion of such patients exhibit
a suboptimal haematologic response to ESA, which in
most cases is due to inadequate iron supply to the eryth-
ron [1]. Concomitant iron supplementation is therefore
required in as many as 90% of EPO-treated individuals
[5].
In haemodialysis populations, several investigations,
including a randomised controlled trial, have consistently
demonstrated that intravenous iron supplementation is
superior to oral iron replacement with respect to enhanc-
ing body iron stores, augmenting haemoglobin levels and
reducing EPO requirements [5-7]. However, there is ongo-
ing controversy as to whether iron supplementation is
best administered orally or intravenously in peritoneal
dialysis (PD) patients (and pre-dialysis patients), in
whom repeated intravenous cannulation is logistically
more difficult. Our group recently performed a cross-over
trial of oral iron versus 2-monthly intravenous iron infu-
sions in 28 PD patients and demonstrated that IV iron
supplementation was associated with a much lower inci-
dence of gastrointestinal disturbances (11% versus 46%, p
< 0.05) and superior haemoglobin levels and body iron
stores, but exceeded the cost of oral iron treatment by 6.5-
fold [8]. Other investigators have similarly demonstrated
that oral iron supplements are unable to maintain ade-
quate iron stores in PD patients over medium-to-long
term periods [5], principally because of poor compliance,
gastrointestinal side effects, suboptimal gastrointestinal
absorption of iron (particularly in the presence of an acute
phase response and high ferritin levels), and medication
costs [9]. In spite of this evidence, many authors [10-12]
and clinical practice guidelines [13-15] have recom-
mended oral iron supplementation for PD patients in the
first instance, because of its greater simplicity, lower cost
and avoidance of the need for repeated intravenous can-
nulation.
The development of an oral iron supplement which
safely, cheaply and more effectively maintains iron stores
and haemoglobin levels in ESP-treated PD patients would
therefore be of considerable clinical utility. Preliminary
evidence suggests that heme iron polypeptide (HIP) may
represent such a promising, novel, therapeutic strategy.
HIP is produced by hydrolysis of bovine haemoglobin
resulting in a highly soluble heme moiety that contains
more than 1% iron. Since heme is absorbed via a different
receptor to that utilised by nonheme (ionic) iron [16,17],
the absorption kinetics and gastrointestinal side effect
profiles of HIP and ionic iron are dissimilar. Administra-
tion of HIP to 14 healthy subjects was associated with
fewer side effects and significantly higher bioavailability
compared with nonheme iron [18]. Specifically, the study
demonstrated that HIP increased serum iron levels 23
times greater than ferrous fumarate on a milligram-per-
milligram basis. One of the possible reasons for why
heme iron is more bioavailable than ionic iron is thought
to be due the fact that the gastrointestinal absorption of
heme iron is far less affected by dietary constituents, such
as polyphenolic tannins, phytates, soy and dairy products
[18]. Hallberg et al [19] also demonstrated that the
absorption of heme iron may be more than 10 times
greater than that of iron salts in subjects with serum ferri-
tin levels greater than 400 ng/mL (898 pmol/L). Moreo-
ver, the gastrointestinal absorption of both heme and
non-heme iron is significantly increased by stimulation
with ESA [20]. Recently, Nissenson et al [21] performed
an open-label, pre-test/post-test trial of HIP (1 tablet tds)
administered in lieu of intravenous iron supplementation
to 37 ESA-treated haemodialysis patients over a 6 month
period. Although 4 (11%) of 37 patients dropped out due
to gastrointestinal intolerance (n = 3) or insufficient iron
supplementation (n = 1) and 5 patients (14%) were
excluded due to unrelated complications or protocol vio-
lation, HIP successfully replaced IV therapy in the major-
ity of patients, resulting in maintenance of haematocrit
targets and iron stores and significant improvement in
EPO efficiency (mean EPO dose/haemoglobin levels fell
from 1270 to 1023 U.g/mo/dL, p = 0.04). However, the
results of this study were significantly limited by its open
label non-randomised design, potential for co-interven-
tion and observer biases, high drop-out rate (25% over 6
months) and failure to analyse on an intention to treat
basis. There have been no other trials of HIP in chronic
kidney disease patients (including PD patients).
Methods/Design
Objectives
The primary objective is to determine whether oral HIP
administration (two tablets nocte per os, equivalent to 24
mg elemental iron per day) results in significantly higher
transferrin saturation (TSAT) values in PD patients treated
with DPO at 6 months compared with conventional oral
slow-release ferrous sulphate supplementation (two tab-
lets nocte per os, equivalent to 210 mg elemental iron per
day).
The secondary objectives will be to determine whether
oral HIP administration (two tablets nocte per os, equiva-BMC Nephrology 2009, 10:20 http://www.biomedcentral.com/1471-2369/10/20
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lent to 24 mg elemental iron per day) to DPO-treated PD
patients over 6 months results in
a) an increase in serum ferritin concentrations;
b) an increase in haemoglobin levels;
c) a reduction in the prescribed dosages of DPO
(Aranesp®, Amgen);
d) a reduction in Key's index (DPO dosage divided by
haemoglobin concentration); and,
e) a reduction in significant side effects (especially gas-
trointestinal side effects).
Ethics approval for the HEMe iron polypeptide Against
Treatment with Oral Controlled Release Iron Tablets trial
(HEMATOCRIT trial) has been obtained from the local
Institutional Ethics Committee in all participating centres
prior to study initiation and patient enrolment. The study
will be performed in accordance with the 2000 Edin-
burgh, Scotland Revision of the Declaration of Helsinki,
the National Health and Medical Research Committee
(NHMRC) Statement on Human Experimentation, Joint
NHMRC/AVCC Statement and Guidelines on Research
Practice, applicable ICH guidelines and the Therapeutic
Goods Administration (TGA) – Note for guidance on
good clinical practice (CPMP/ICH/135/95) annotated
with TGA.
Participants
The study population includes adult (18 years or over)
patients willing to give informed consent who have been
on PD for > 1 month and receiving DPO for > 1 month.
Patients will be recruited by local investigators from PD
units at three Australian centres. The clinical and demo-
graphic characteristics of this population are comparable
to those reported for the Australian and New Zealand PD
population by the ANZDATA Registry. This, along with
the multicentre nature of the trial will enhance its gener-
alisability.
Exclusion criteria include:
1. Patients with a history of psychological illness or con-
dition which interferes with their ability to understand or
comply with the requirements of the study.
2. Pregnancy or breast-feeding.
3. Known hypersensitivity to, or intolerance of, oral iron,
HIP or DPO.
4. Active peptic ulcer disease.
5. Vitamin B12 or folate deficiency.
6. Recent (within 1 month) acute infection.
7. Parathyroid hormone level > 100 pmol/L.
8. Serum aluminium > 2 μmol/L.
9. Presence of systemic haematological disease (including
antibody-mediated pure red cell aplasia) or known hae-
moglobinopathy
10. Major surgery, infection, acute myocardial infarction
or malignancy within the last 3 months.
11. Intravenous iron therapy, vitamin C therapy, mela-
tonin treatment, androgen therapy or blood transfusion
within the previous month.
12. Serum ferritin ≥ 500 μg/mL or transferrin saturation
(TSAT) ≥ 50%.
13. Religious or other objection to consuming product
prepared from bovine blood.
Study design
The study is a prospective, open-label, randomised con-
trolled trial. Patients will be randomised to one of two
treatment groups in equal proportion (Figure 1). To
ensure adequate concealment of allocation, the randomi-
sation will be performed using sequentially numbered,
opaque, sealed envelopes, stratified for the presence or
absence of a TSAT ≤ 20%. The sequence of interventions
was obtained from a computer-generated random
number list in permuted blocks provided through the
Australasian Kidney Trials (AKTN) network.
Experimental Intervention
HIP (Proferrin®ES, Colorado Biolabs, USA) is approved
for use as a dietary/nutritional supplement in Canada and
the United States of America. The usual dose is 1 tablet
(equivalent to 12 mg elemental iron) taken twice or thrice
daily, either with or without food. The side effects
reported with HIP are similar to those associated with
conventional oral iron preparations and include nausea,
vomiting and constipation. However, trials in healthy
individuals [18] and in haemodialysis patients [21] sug-
gest that the incidence of such adverse drug reactions is
relatively low, possibly due to the different absorption
characteristics of heme versus non-heme iron. For exam-
ple, in a study of 37 haemodialysis patients receiving HIP
for 6 months, constipation occurred in 3 (8%) patients
and was the only observed adverse effect of the agent. The
dose of HIP used in that investigation (3 tablets per day)
was 50% higher than that proposed in the present studyBMC Nephrology 2009, 10:20 http://www.biomedcentral.com/1471-2369/10/20
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(2 tablets per day). There are no other published data con-
cerning the side effect profile of HIP in end-stage renal
failure patients. Concern has previously been expressed
about the possibility of transmission of bovine spongi-
form encephalopathy (BSE) through the consumption of
bovine tissue [21]. Currently, HIP is manufactured from
red blood cells of cows of American origin, and both the
US Department of Agriculture and Food and Drug Admin-
istration (FDA) currently maintain that the United States
is free of BSE. In addition, the putative infectious agents
for BSE, conformationally shifted neuronal membrane
copper-binding proteins called prions, usually are not
found in blood [21]. Thus, the risk of BSE from taking HIP
is negligible.
Control Intervention
Slow-release ferrous sulphate (Ferrogradumet®, Abbott,
Sydney, Australia) is registered in Australia for use as an
oral iron supplement and is one of the most common
supplements prescribed in dialysis populations. The usual
recommended dose is 2 to 3 tablets a day (equivalent to
210 to 315 mg of elemental iron per day). However, gas-
trointestinal side effects (especially constipation) usually
limit the maximum dosage in end-stage renal failure
patients to 2 tablets per day (the dose proposed in the cur-
rent study). The side effects reported with Ferro-Gradumet
are similar to those associated with other conventional
oral iron preparations, although the incidence may be
lower due to the controlled release nature of the formula-
tion. They are as follows: nausea, vomiting, abdominal
pain or discomfort, blackening of stools, diarrhoea and
constipation. In a study of 28 PD patients at Princess Alex-
andra Hospital, oral Ferrogradumet® administration in a
dose of 2 tablets per day for 4 months was associated with
significant gastrointestinal side effects in 46% of patients
(constipation 38%, nausea 19%, abdominal pain 4%). A
randomised, placebo-controlled trial of oral ferrous sul-
phate in 32 consecutive iron-replete dialysis patients sim-
ilarly revealed significant gastrointestinal side effects in
50% of subjects [22]. Ferrous sulphate absorption is sig-
nificantly inhibited by concomitant food and phosphate
binder medications. Consequently, subjects participating
in the present trial will be instructed to take their study
medications on an empty stomach and at least 2 hours
apart from phosphate binder ingestion.
Concurrent Treatments
Vitamin B and folic acid supplementation are permitted.
Vitamin C supplementation, melatonin and androgen
therapy are prohibited during the study period.
Blinding
Blinding is not able to be performed as it is not possible
to formulate identical-appearing preparations of HIP and
slow-release iron. The controlled release iron tablets are
too large to enclose in capsules and cannot be cut or
ground. Consequently, the study will follow an open label
design. An individual patient's participation in the study
will cease at the end of the 6 month study period. If,
before this time, the patient experiences severe anaemia
(<65 g/L), symptomatic anaemia or the patient's attend-
ing physician believes that additional therapy is required
(eg blood transfusion), they will be considered to have
reached an end-point and will be withdrawn from study
medication, but will still be followed up, with outcomes
measured.
Outcome measures
The primary outcome measure will be the difference in
TSAT values between the HIP and ferrous sulphate groups
at the end of the 6 month study period.
The secondary outcome measures will be the differences
between the 2 groups at the end of the 6 month study
period with respect to serum ferritin concentration, hae-
Trial schema Figure 1
Trial schema.
ESP-treated PD patients (n=60)
1. On peritoneal dialysis ≥ 1 month.
2. On DPO for ≥ 1 month
3. 18 years or over.
4. Able to give informed consent.
5. No clear cause for anaemia identified.
(other than  uraemia or iron deficiency)
6. Ferritin < 500 μg/mL & TSAT < 50%
Ferrous sulphate SR
1 tablet b.d. p.o.
(n=30)
HIP
1 tablet b.d.. p.o
(n=30).
1:1
Primary outcome measure:
TSAT difference between 2 groups
6 months observation
(2-monthly TSATs)
Randomization
(stratified by TSAT)
ESP-treated PD patients (n=60)
1. On peritoneal dialysis ≥ 1 month.
2. On DPO for ≥ 1 month
3. 18 years or over.
4. Able to give informed consent.
5. No clear cause for anaemia identified.
(other than  uraemia or iron deficiency)
6. Ferritin < 500 μg/mL & TSAT < 50%
Ferrous sulphate SR
1 tablet b.d. p.o.
(n=30)
HIP
1 tablet b.d.. p.o
(n=30).
1:1
Primary outcome measure:
TSAT difference between 2 groups
6 months observation
(2-monthly TSATs)
Randomization
(stratified by TSAT)BMC Nephrology 2009, 10:20 http://www.biomedcentral.com/1471-2369/10/20
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moglobin level, DPO dosage, Key's index (DPO dosage
divided by haemoglobin) and incidence of adverse events.
Procedures
Patients will take 2 tablets (HIP or ferrous sulphate) nocte
for a period of 6 months. They will be instructed to take
their study medications on an empty stomach and at least
2 hours apart from phosphate binder ingestion. At the
time of inclusion in the study, demographic and clinical
data will be recorded. All patients will be allowed their
usual diet during the study period. DPO dosages will
modified according to unit protocols, based on haemo-
globin level. Full blood counts will be measured monthly,
as per usual clinical practice. Iron studies will be measured
every 2 months, as usual clinical practice. Patients will
receive a medical review by their nephrologists every 2
months, as per usual clinical practice. No other procedure
will be undertaken and all other care (including blood
tests) will be provided according to standard unit proto-
cols. Figure 2 outlines the trial schedule.
An individual patient's participation in the study will
cease at the end of the 6 month study period. If, before
this time, the patient experiences severe anaemia (<65 g/
L), symptomatic anaemia (e.g. new onset or worsening
shortness of breath or ischaemic chest pain attributable to
the low haemoglobin) or the patient's attending physician
believes that additional therapy is required (eg blood
transfusion), they will be considered to have reached an
end-point and will be withdrawn from study medication,
but will still have blood counts measured monthly and
followed for study outcomes. A patient's participation in
the study will also cease if, during the course of the study,
they complete PD therapy (eg renal transplantation or
conversion to haemodialysis).
Adverse Events
The number and proportion of subjects who report treat-
ment-emergent adverse events will be summarized for
each treatment group. Treatment emergent events include
events that start on or after Day 0 of the study [that is the
first day of Study Drug administration], and were not
present at baseline, or were present at baseline, but
increased in severity after the start of the study. The Medi-
cal Dictionary for Regulatory Activities [MedDRA] Termi-
nology will be used to classify all adverse events with
rESAect to System Organ Class [SOC], high level group
term (HLGT), and preferred term.
For the purposes of this study, anaemia (serum Hgb or
Hct below the normal range or worsened from baseline)
will not be considered an adverse event unless it reaches a
severe level (<65 g/L) or is associated with significant
symptoms. Similarly, iron deficiency (iron indices below
the normal range or worsened from baseline) will not be
considered an adverse event.
Sample size calculations
Prospective power calculations indicate that the study will
have adequate statistical power (80% probability) to
detect a clinically significant increase in TSAT of 7%,
assuming α = 0.05 and a population standard deviation of
8%, if 44 patients were recruited in the study (22 in each
group). Allowing for a 15% drop-out rate over 6 months
using the adjustment formula of 1/[1 - drop-out rate] 2, we
aim to recruit a total of 60 patients (30 in each group). We
anticipate that a recruitment period of 18 months will be
required. The assumptions for these power calculations
were based on a previous randomised controlled trial of
oral versus intravenous iron supplementation in PD
patients [8], in which the baseline values were 107 ± 3 g/
L for haemoglobin, 24.2 ± 1.7% for transferrin saturation
and 323 ± 46 μg/L for serum ferritin concentration. Based
on these assumptions, we estimate the power of the study
for secondary outcome measures to be 77% for serum fer-
ritin (δ 150 μg/mL, σ 180 μg/mL), 62% for haemoglobin
(δ 7 g/L, σ 10 g/L), 22% for DPO divided by haemoglobin
(δ 0.00075 μg.L/kg.g/week, σ 0.002 μg.L/kg.g/week) and
93% for the occurrence of gastrointestinal events (HIP 8%
vs ferrous sulphate 46%).
Trial schedule (all tests are ordered as per routine clinical practice) Figure 2
Trial schedule (all tests are ordered as per routine clinical practice).
Time Post-Randomisation (months)  Test 
0 1 2 3 4 5 6
History  X  X  X  X 
Physical  Examination  X  X  X  X 
Adverse  Event  Assessment  X  X  X  X 
Full  Blood  Count  X X X X X X X 
Chemistry  Profile  X X X X X X X 
Iron  Studies  (inc.  TSAT,  Ferritin)  X X X X X X X BMC Nephrology 2009, 10:20 http://www.biomedcentral.com/1471-2369/10/20
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The assumptions used for the power calculations are con-
servative and based on our previous study in 28 PD
patients [22] and that of Nissenson et al in 37 haemodial-
ysis patients 1. Because of power considerations and the
relatively short duration of the study, no interim analysis
is planned.
Statistical analysis
Primary Outcome Analyses
Differences between the intervention and control groups
with respect to the primary outcome measure (TSAT level
at 6 months) will be measured by comparison of the
mean TSAT in each group, adjusted for baseline values
(analysis of covariance). Data will be analysed on an
intention to treat basis. For patients withdrawing before
the end of the 6 month study, their TSAT at the time of
withdrawal will be taken as their final haemoglobin.
Secondary Outcome Analyses
Secondary analysis will be performed by repeated meas-
ures analysis of covariance with and without adjustment
for baseline characteristics. The analyses used for second-
ary outcome measures will include unpaired t-test (serum
ferritin, Key's index), Mann-Whitney U-test (DPO dosage)
and chi square test (adverse drug reactions).
Categorical baseline characteristics (e.g. sex, race, comor-
bid illnesses, etc.) will be summarized with the number
and percent of subjects in each treatment group with the
characteristic. Quantitative characteristics (e.g., age and
weight) will be summarized by mean and standard devia-
tion or median [interquartile range], depending on data
distribution. The number and percent of subjects who are
randomised, treated with randomized Study Drug, require
intervention, prematurely discontinue, and complete the
study will be summarized. Fisher's exact test or the Chi-
square test will be used to assess treatment group differ-
ences in the proportions of subjects who require interven-
tion and who complete the study. The number and
percent of subjects will be summarised for each reason for
premature discontinuation.
Discussion
This investigator-initiated multicentre Australian study
has been designed to provide evidence to help nephrolo-
gists and their CKD patients better determine whether HIP
(Proferrin®ES) will more effectively augment iron stores in
ESP-treated PD patients than conventional oral iron sup-
plementation. Concomitant iron supplementation is
required in as many as 90% of ESP-treated individuals [5].
However, the optimal means of administering iron to PD
patients remains unclear: administration of intravenous
iron is logistically difficult and costly, while conventional
oral iron supplementation is also associated with poor
compliance, gastrointestinal side effects and suboptimal
GI absorption of iron [9]. Thus, the development of an
oral iron supplement which is able to safely, cheaply and
more effectively maintain iron stores and haemoglobin
levels in ESP-treated PD patients would fulfil a currently
unmet clinical need.
The multicentre nature of this trial will greatly enhance its
generalisability. Moreover, the trial sample size has been
carefully and prospectively calculated using a minimum
clinically important difference in TSAT of 7% and realistic
estimates of trial drop-out and non-compliance rates to
minimise the risk of a type 2 statistical error.
It is hoped that results will be available in 2010. Demon-
stration of a significant improvement in iron stores with
oral HIP therapy will provide clinicians with an important
new therapy for effectively combating inadequate iron
stores in PD patients.
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